ResearcherChinese PLA General HospitalNo recent work listed

Li Bai

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-0331-4342; OpenAlex author ID A5100608935. Sources: OpenAlex.

Their work

Papers: 2 (first author 1, last author 1)
Trials: 0
Grants: 0
Labs led: 1
Collaborators: 3

Papers, trials and grants by year

2014: 1 paper · 2015: none · 2016: none · 2017: none · 2018: 1 paper

Papers 2

Comparison and validation of the value of preoperative inflammation marker-based prognostic scores in resectable pancreatic ductal adenocarcinoma. First author DOI 10.2147/cmar.s173444 ↗
Efficacy of nimotuzumab plus gemcitabine usage as first-line treatment in patients with advanced pancreatic cancer. Last author DOI 10.1007/s13277-013-1306-x ↗

Closest collaborators

The 3 strongest of 3 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Sisi Ye · 1 shared paper, 2018 · strength 0.17
- Paper Comparison and validation of the value of preoperative inflammation marker-based prognostic scores in resectable pancre… DOI 10.2147/cmar.s173444 ↗
Shunchang Jiao · 1 shared paper, 2014 · strength 0.05
- Paper Efficacy of nimotuzumab plus gemcitabine usage as first-line treatment in patients with advanced pancreatic cancer. DOI 10.1007/s13277-013-1306-x ↗
Dan Su · 1 shared paper, 2014 · strength 0.05
- Paper Efficacy of nimotuzumab plus gemcitabine usage as first-line treatment in patients with advanced pancreatic cancer. DOI 10.1007/s13277-013-1306-x ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.